Research Paper Volume 14, Issue 2 pp 869—891

Novel necroptosis-related gene signature for predicting the prognosis of pancreatic adenocarcinoma

Zixuan Wu1, , Xuyan Huang1, , Minjie Cai2, , Peidong Huang3, , Zunhui Guan4, ,

  • 1 Guangzhou University of Chinese Medicine, Guangzhou, Guangdong Province 510006, China
  • 2 Shantou Health School, Shantou, Guangdong Province 515061, China
  • 3 Yunnan University of Chinese Medicine, Kunming, Yunnan Province 650500, China
  • 4 Kunming Municipal Hospital of Traditional Chinese Medicine, Kunming, Yunnan Province 650011, China

Received: November 4, 2021       Accepted: January 11, 2022       Published: January 24, 2022
How to Cite

Copyright: © 2022 Wu et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Pancreatic adenocarcinoma (PAAD) is a deadly digestive system tumor with a poor prognosis. Recently, necroptosis has been considered as a type of inflammatory programmed cell death. However, the expression of necroptosis-related genes (NRGs) in PAAD and their associations with prognosis remain unclear. NRGs’ prediction potential in PAAD samples from The TCGA and GEO datasets was investigated. The prediction model was constructed using Lasso regression. Co-expression analysis showed that gene expression was closely related to necroptosis. NRGs were shown to be somewhat overexpressed in high-risk people even when no other clinical symptoms were present, indicating that they may be utilized in a model to predict PAAD prognosis. GSEA showed immunological and tumor-related pathways in the high-risk group. Based on the findings, immune function and m6A genes differ significantly between the low-risk and high-risk groups. MET, AM25C, MROH9, MYEOV, FAM111B, Y6D, and PPP2R3A might be related to the oncology process for PAAD patients. Moreover, CASKIN2, TLE2, USP20, SPRN, ARSG, MIR106B, and MIR98 might be associated with low-risk patients with PAAD. NRGs and the relationship of the immune function, immune checkpoints, and m6A gene expression with NRGs in PAAD may be considered as potential therapeutic targets that should be further studied.


PAAD: Pancreatic adenocarcinoma; GO: Gene ontology; AUC: Areas under the curve; MF: Molecular functions; ICIs: Immune checkpoint inhibitors; ROC: Receiver-operating characteristics; GSEA: Gene set enrichment analyses; TCGA: The Cancer Genome Atlas; NRGs: Necroptosis-related genes; BP: Biological processes; CC: Cellular components; OS: Overall survival; GEO: Gene Expression Omnibus; DEGs: Differentially expressed genes; KEGG: Kyoto Encyclopedia of Genes and Genomes.